Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/07/16/2913605/0/en/EyePoint-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/06/26/2904464/0/en/EyePoint-Pharmaceuticals-to-Highlight-DURAVYU-vorolanib-intravitreal-insert-Clinical-and-Regulatory-Progress-and-Pipeline-Innovation-at-R-D-Day-2024.html
https://www.globenewswire.com/news-release/2024/06/18/2900251/0/en/EyePoint-Pharmaceuticals-to-Host-R-D-Day-on-June-26-2024.html
https://www.globenewswire.com/news-release/2024/06/17/2899495/0/en/EyePoint-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/06/05/2893725/0/en/EyePoint-Pharmaceuticals-to-Present-at-Goldman-Sachs-45th-Annual-Global-Healthcare-Conference.html
https://www.globenewswire.com/news-release/2024/05/16/2883257/0/en/EyePoint-Pharmaceuticals-Reports-Inducement-Grants-Under-NASDAQ-Listing-Rule-5635-c-4.html
https://www.globenewswire.com/news-release/2024/05/08/2877660/0/en/EyePoint-Pharmaceuticals-Reports-First-Quarter-2024-Financial-Results-and-Highlights-Recent-Corporate-Developments.html
https://www.globenewswire.com/news-release/2024/05/06/2875682/0/en/EyePoint-Pharmaceuticals-Announces-Topline-Data-from-the-Phase-2-PAVIA-Trial-of-DURAVYU-in-Non-Proliferative-Diabetic-Retinopathy.html
https://www.fiercepharma.com/drug-delivery/eyepoint-reports-midstage-trial-fail-duravyu-raising-questions-about-program
https://www.defenseworld.net/2024/04/27/mirae-asset-global-investments-co-ltd-purchases-882-shares-of-eyepoint-pharmaceuticals-inc-nasdaqeypt.html#google_vignette